CG:600993 Mayinglong Pharmaceutical Group Co., LTD

Mayinglong Pharmaceutical Group Co,.LTD is principally engaged in pharmaceutical production, wholesaling and retailing businesses. The Company’s pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for colpitis, including metronidazole suppositories and clotrimazole suppositories; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also involves in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products primarily in domestic market.

22.43 CNY
As of 01/26/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  China
Country of incorporation:  China
IPO date:  05/18/2004
Stock exchange:    Shanghai Stock Exchange
Exchange country:   China
Market cap:   9,974,589,440 CNY
Current dividend yield:   1.28%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy